RxDoctor Payments Data

Keith Eaton, MD

Medical Oncology · Seattle, WANPI 1982784955

Payments from drug & device makers

What this record shows

That places this record below the midpoint for medical oncology clinicians in WA, where the typical reported total is $2,355.

No general payments reported

No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.

$356,269in research payments, 2019–2025

Across 14 payments — averaging $25,448 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Mirati Therapeutics, Inc.$348K
  • Seagen Inc.$8K

How this compares

$0 in reported general payments places this provider in the 5th percentile of 162 medical oncology providers in Washington.

See all medical oncology providers in Washington

Medicare billing

Part B allowed, 2024
$44,564
Medicare patients
122
Services billed
405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TagrissoOsimertinib Mesylate31$506,240
TabrectaCapmatinib Hydrochloride12$274,368
Ondansetron Hcl11$151

Paid to pharmacies, not to this prescriber.

Other medical oncology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →